Vericel (VCEL) Depreciation & Amortization (CF) (2010 - 2026)
Vericel (VCEL) posted Depreciation & Amortization (CF) of $3.6 million for Q2 2026, up 10.81% sequentially from $3.3 million in Q1 2026, and up 28.1% YoY from $2.8 million in Q2 2025.
Analysis
Vericel (VCEL) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
Vericel has reported Depreciation & Amortization (CF) for 17 years, with the latest figure at $3.6 million in Q2 2026.
- Quarterly Depreciation & Amortization (CF) rose 28.1% year-over-year to $3.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $12.9 million (up 55.37% YoY) and the FY2025 annual result came in at $11.5 million, up 109.74% from the prior year.
- Depreciation & Amortization (CF) climbed to $3.6 million in Q2 2026 per VCEL's latest filing, from $3.3 million in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $3.6 million in Q2 2026 and troughed at $873000.0 in Q1 2022.
- A 5-year average of $1.8 million and a median of $1.3 million in 2024 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2023 and 2025: Depreciation & Amortization (CF) increased 6.45% in 2023, then jumped 122.02% in 2025.
- Over 5 years, Depreciation & Amortization (CF) stood at $1.0 million in 2022, then advanced by 10.59% to $1.1 million in 2023, then grew by 28.55% to $1.5 million in 2024, then surged by 109.07% to $3.1 million in 2025, then rose by 17.23% to $3.6 million in 2026.
- According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $3.6 million, $3.3 million, and $3.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 40.52 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Vericel | 2.05 Bn | 1.89 Bn | 56.40 Mn | 3.62 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 3.62 Mn |
| Mar 31, 2026 | 3.27 Mn |
| Dec 31, 2025 | 3.09 Mn |
| Sep 30, 2025 | 2.94 Mn |
| Jun 30, 2025 | 2.83 Mn |
| Mar 31, 2025 | 2.69 Mn |
| Dec 31, 2024 | 1.48 Mn |
| Sep 30, 2024 | 1.33 Mn |
| Jun 30, 2024 | 1.32 Mn |
| Mar 31, 2024 | 1.38 Mn |
| Dec 31, 2023 | 1.15 Mn |
| Sep 30, 2023 | 1.15 Mn |
| Jun 30, 2023 | 1.17 Mn |
| Mar 31, 2023 | 1.16 Mn |
| Dec 31, 2022 | 1.04 Mn |
| Sep 30, 2022 | 1.00 Mn |
| Jun 30, 2022 | 1.10 Mn |
| Mar 31, 2022 | 873,000.00 |
| Dec 31, 2021 | 765,000.00 |
| Sep 30, 2021 | 700,000.00 |